# adc-conjugation-guide
A curated guide and decision-support tool to aid scientists in selecting optimal conjugation strategies for antibody-drug conjugates (ADCs), including summaries of current technologies, platform comparisons, and use-case recommendations.

# ADC Conjugation Platform Recommender

This repository provides a structured, practical resource for selecting the right conjugation method for antibody-drug conjugates (ADCs). It is based on the 2025 review by WuXi XDC and includes comparative analysis of Random, Site-Specific Non-Selective, and Site-Specific Selective technologies.

## ğŸ§  Features

- Technology overviews and pros/cons
- Decision trees and scoring templates
- DAR (Drug-Antibody Ratio) calculation tools
- Summary of platforms like WuXiDAR4â„¢, SMARTagÂ®, THIOMABâ„¢, etc.
- Peer-reviewed references for in-depth reading

## ğŸ“Š Quick Comparison

| Strategy                          | DAR Control | Complexity | Scalability | Homogeneity | Example Platforms        |
|----------------------------------|-------------|------------|-------------|-------------|--------------------------|
| Random Conjugation               | Low         | Low        | High        | Low         | NHS-Lysine, Maleimide    |
| Site-Specific, Non-Selective     | Medium      | Medium     | Medium      | Medium      | GlycoConnectâ„¢, Enzymatic |
| Site-Specific and Selective      | High        | High       | Medium      | High        | WuXiDAR4â„¢, THIOMABâ„¢      |

## ğŸ“Š ML Prediction Flow Diagram

â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘     ğŸ§ª User Inputs (via Gradio Interface)     â•‘
â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£
â•‘ - Technology_Category                        â•‘
â•‘ - DAR_Mean, DAR_Std, DAR_CV                  â•‘
â•‘ - Stability_Score, Expression_Ease           â•‘
â•‘ - Homogeneity, Cost_Index                    â•‘
â•‘ - CMC_Risk, Approved_Usage, Vendor           â•‘
â•‘ - Scalability, Latency_to_Clinic_yrs         â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
                â”‚
                â–¼
â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘     ğŸ§¹ Data Preprocessing Pipeline (in .pkl)  â•‘
â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£
â•‘ - Convert categoricals to string             â•‘
â•‘ - One-hot / ordinal encoding                 â•‘
â•‘ - Normalize/scale numerical values           â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
                â”‚
                â–¼
â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘     ğŸ§  Trained ML Model (e.g., Random Forest) â•‘
â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£
â•‘ - Trained on historical ADC project data     â•‘
â•‘ - Learns platform suitability from patterns  â•‘
â•‘ - Outputs platform label                     â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
                â”‚
                â–¼
â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘   âœ… Predicted Conjugation Platform Label     â•‘
â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£
â•‘ Example: "Lysine-Based"                      â•‘
â•‘ Displayed in Gradio interface                â•‘
â•‘ Exported in a downloadable PDF report        â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•


## ğŸ” References

See [`references/key_publications.md`](references/key_publications.md) for foundational and recent literature, including:

- WuXi XDC, *Antibody Therapeutics* (2025)
- Beck et al., *Nat Rev Drug Discov* (2020)
